Abstract: The present invention relates to nucleic acid probes specific to Staphylococcus aureus, which is useful for detecting and identifying S. aureus in a biological sample. More particularly, the present invention relates to a DNA chip for detecting and identifying S. aureus, on which nucleic acid probes derived from 23 S rRNA gene of S. aureus are immobilized. The application of the DNA chips according to the present invention allows time-saving and accurate diagnosis of bacterial infection compared with the conventional bacterial culture methods.

Abstract: The present invention relates to nucleic acid probes specific to E. coli, which is useful for detecting and identifying E. coli in a biological sample. More particularly, the present invention relates to a DNA chip for detecting and identifying E. coli, on which nucleic acid probes derived from 23 S rRNA gene of E. coli are immobilized. The application of the DNA chip according to the present invention allows time-saving and accurate diagnosis of bacterial infection compared with the conventional of bacterial culture methods. In addition, it is not affected by antibiotics addition in clinical practice, thus leading to more accurate diagnosis.

Abstract: The present invention relates to oligonucleotides for diagnosis of corneal dystrophy. More particularly, the present invention relates to oligonucleotides for detecting mutation of BIGH3 gene for diagnosis or corneal dystrophy including Avellino corneal dystrophy, which must be precisely diagnosed before vision correction surgery, and a DNA chip for diagnosis of corneal dystrophy, which has the oligonucleotides fixed thereon. According to the present invention, conventional microscopic diagnosis of corneal dystrophy can be replaced with a precise genetic method, which prevents a patient with corneal dystrophy from losing eyesight by eyesight correction surgery after erroneous diagnosis.

Abstract: The present invention relates to a diagnostic cancer marker using variation of a granulocyte colony stimulating factor (G-CSF) gene and a method for preparing the same, and more specifically, relates to a method for diagnosing cancer and/or assessing the state of cancer progression using an oligonucleotide having the 3?-terminal end of exon 2 region linked to the 5?-terminal end of exon 4 region of a G-CSF gene as a diagnostic cancer marker. According to the present invention, cancer can be quickly and exactly diagnosed using variation in a G-CSF gene expression.

Abstract: The present invention relates to a pharmaceutical composition for the treatment of nerve damage, and more particularly to a pharmaceutical composition for the treatment of nerve damage, which contains blood plasma or serum as an active ingredient. The inventive composition regenerates nerve cells after spinal nerve damage and provides complete structural continuity in the spinal nerve lesion sites. Thus, the composition is useful for the treatment of nerve damage.

Abstract: The present invention relates to a pharmaceutical agent for treating Avellino corneal dystrophy, and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy comprising pharmaceutically effective amount of blood plasma or serum as an active ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms by dissolving away hyaline granules in the cornea of a patient with severe Avellino corneal dystrophy due to LASIK surgery.

Abstract: The present invention relates to a medicine for treating Avellino corneal dystrophy (ACD), and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy containing an antibody against TGF-? as an effective ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms of a patient with severe Avellino corneal dystrophy due to TGF-? induced by exposure to intense light, such as UV etc.

Abstract: The present invention relates to a composition for treating alopecia or promoting hair growth, which contains the blood plasma or serum as an active ingredient. The inventive composition is effective in hair growth, hair growth promotion and hair loss prevention.